New insights into PD-1 formation could greatly improve treatments
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
List view / Grid view
A single change in the amino acid structure of the transmembrane segment can either enhance or diminish the inhibitory function of PD-1 in immune responses.
Researchers have designed the first small molecule drug targeting K-Ras GD12, which could improve pancreatic cancer outcomes.
After gaining her PhD in Biophysics as an International Max-Planck Research School scholar, Leila joined the nuclear field in 2006, starting as an engineer in radiation protection and neutron fluence. Throughout Leila’s career, she has worked across multiple disciplines as a technical project lead in nuclear engineering, lastly in the…
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted…
Dr Amber Van Laar shares her remarkable journey in STEM. From a childhood fascination with science and medicine to a pivotal role as VP Clinical Development, AskBio. In this interview, she explores the profound impact of her early exposure to neuro-oncology, the challenges faced as a physician-scientist, and the pursuit…
28 February 2024 | By Eurofins DiscoverX
Join the webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity…
Amidst the transformative era of AI in drug discovery, this report focuses on recent advancements, notably the development of highly accurate drug target models, and how AI is revolutionising precision in identifying drug targets.
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
Researchers have created a nanomedicine loaded with siRNAs, which demonstrated a 73 percent reduction in HIV replication.
Researchers have found that using protein-like polymers to inhibit the Keap1/Nrf2 PPI is a powerful therapeutic strategy.
Introducing Dr Beate Mueller-Tiemann, whose journey spans continents and disciplines, with a passion for biochemistry and molecular biology since her high school days. From elucidating pivotal proteins in cancer to monoclonal antibody discovery, Dr Mueller-Tiemann's contributions have not only transformed our understanding of diseases but have also fuelled research in…
The International Day for Women and Girls in Science: we have the privilege of engaging with Denise Bowser, a distinguished figure with a remarkable journey at Onyx Scientific. Join us as we explore Denise's experiences, the milestones and challenges she has encountered while navigating the dynamic landscape of the pharmaceutical…
While blood tests measuring prostate-specific antigen (PSA) levels have been a primary screening tool, their limitations in specificity have led to challenges such as overdiagnosis and overtreatment. Cleveland Diagnostics is pioneering an alternative approach with the IsoPSA test, focusing on assessing the structure of the PSA protein rather than its…
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Dr Sara Sangha, Associate Vice President of Medical Affairs and Head of US Medical Aesthetics at AbbVie. Over her almost 20 years with Allergan…